# A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

> **NCT02354950** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 16 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK1265744 30mg

## Key facts

- **NCT ID:** NCT02354950
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-22
- **Primary completion:** 2016-09-16
- **Final completion:** 2016-09-16
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354950, "A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02354950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*